Eloxx Pharmaceuticals (NASDAQ: ELOX) recently received a number of ratings updates from brokerages and research firms:
- 8/1/2026 – Eloxx Pharmaceuticals was upgraded by Wall Street Zen to “hold”.
- 7/22/2026 – Eloxx Pharmaceuticals is now covered by Lifesci Capital. They set an “outperform” rating and a $40.00 price target on the stock.
- 7/20/2026 – Eloxx Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $43.00 price target on the stock.
- 7/20/2026 – Eloxx Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $43.00 price target on the stock.
Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.
See Also
- Five stocks we like better than Eloxx Pharmaceuticals
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Eloxx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
